Matches in SemOpenAlex for { <https://semopenalex.org/work/W3159012904> ?p ?o ?g. }
Showing items 1 to 75 of
75
with 100 items per page.
- W3159012904 endingPage "368" @default.
- W3159012904 startingPage "368" @default.
- W3159012904 abstract "Ceftaroline fosamil is a novel 5th generation broad-spectrum oxyimino-cephalosporin with activity against Staphylococcus aureus, including methicillin-resistant S. aureus (MRSA), Streptococcus pneumoniae, Haemophilus influenzae, and Gram-negative bacteria. It has been approved by the United States Food and Drug Administration for the treatment of acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia. There have been reported cases of successful treatment of MRSA bacteremia with this agent. Common adverse drug reactions from ceftaroline include skin rash, hives, neutropenia, thrombocytopenia, and anemia. Acute eosinophilic pneumonia is a rare untoward drug reaction associated with it. We report a case of fever and acute hypoxic respiratory failure with bilateral interstitial pulmonary infiltrates while on ceftaroline therapy for sternal osteomyelitis and ascending aortic graft infection secondary to MRSA. Laboratory studies revealed peripheral blood eosinophilia (>3000 cells/mm3). After exclusion of infectious, autoimmune, and other extrinsic allergic causes of pneumonia, ceftaroline-related acute eosinophilic pneumonia was suspected. Ceftaroline was discontinued and a therapeutic trial of high-dose steroid was initiated. Significant improvement of clinical symptoms and hypoxia was achieved after 24 h of steroid therapy. There was no recurrence of clinical symptoms after completing steroid course, which supported our suspicion of acute eosinophilic pneumonia from ceftaroline. Radiographic improvement of pulmonary infiltrates occurred 4 weeks later with complete resolution at 3 months from the initial event. The current case adds to this rarely reported adverse effect from this relatively newer antimicrobial agent. Increased awareness, early recognition, discontinuation of medication, and steroid therapy are key in favorable clinical outcome and recovery." @default.
- W3159012904 created "2021-05-10" @default.
- W3159012904 creator A5012070598 @default.
- W3159012904 creator A5016163621 @default.
- W3159012904 creator A5032191978 @default.
- W3159012904 creator A5064943394 @default.
- W3159012904 creator A5079696064 @default.
- W3159012904 date "2021-01-01" @default.
- W3159012904 modified "2023-10-14" @default.
- W3159012904 title "Ceftaroline-related acute eosinophilic pneumonia" @default.
- W3159012904 cites W2013986205 @default.
- W3159012904 cites W2049833735 @default.
- W3159012904 cites W2087451437 @default.
- W3159012904 cites W2139000046 @default.
- W3159012904 cites W2152009943 @default.
- W3159012904 cites W2343357819 @default.
- W3159012904 cites W2791169338 @default.
- W3159012904 cites W4236781036 @default.
- W3159012904 doi "https://doi.org/10.4103/lungindia.lungindia_908_20" @default.
- W3159012904 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8272419" @default.
- W3159012904 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34259178" @default.
- W3159012904 hasPublicationYear "2021" @default.
- W3159012904 type Work @default.
- W3159012904 sameAs 3159012904 @default.
- W3159012904 citedByCount "2" @default.
- W3159012904 countsByYear W31590129042021 @default.
- W3159012904 countsByYear W31590129042022 @default.
- W3159012904 crossrefType "journal-article" @default.
- W3159012904 hasAuthorship W3159012904A5012070598 @default.
- W3159012904 hasAuthorship W3159012904A5016163621 @default.
- W3159012904 hasAuthorship W3159012904A5032191978 @default.
- W3159012904 hasAuthorship W3159012904A5064943394 @default.
- W3159012904 hasAuthorship W3159012904A5079696064 @default.
- W3159012904 hasBestOaLocation W31590129041 @default.
- W3159012904 hasConcept C126322002 @default.
- W3159012904 hasConcept C142724271 @default.
- W3159012904 hasConcept C177713679 @default.
- W3159012904 hasConcept C2776178081 @default.
- W3159012904 hasConcept C2777714996 @default.
- W3159012904 hasConcept C2777914695 @default.
- W3159012904 hasConcept C2779758542 @default.
- W3159012904 hasConcept C2780942278 @default.
- W3159012904 hasConcept C71924100 @default.
- W3159012904 hasConceptScore W3159012904C126322002 @default.
- W3159012904 hasConceptScore W3159012904C142724271 @default.
- W3159012904 hasConceptScore W3159012904C177713679 @default.
- W3159012904 hasConceptScore W3159012904C2776178081 @default.
- W3159012904 hasConceptScore W3159012904C2777714996 @default.
- W3159012904 hasConceptScore W3159012904C2777914695 @default.
- W3159012904 hasConceptScore W3159012904C2779758542 @default.
- W3159012904 hasConceptScore W3159012904C2780942278 @default.
- W3159012904 hasConceptScore W3159012904C71924100 @default.
- W3159012904 hasIssue "4" @default.
- W3159012904 hasLocation W31590129041 @default.
- W3159012904 hasLocation W31590129042 @default.
- W3159012904 hasLocation W31590129043 @default.
- W3159012904 hasOpenAccess W3159012904 @default.
- W3159012904 hasPrimaryLocation W31590129041 @default.
- W3159012904 hasRelatedWork W2026979049 @default.
- W3159012904 hasRelatedWork W2414368234 @default.
- W3159012904 hasRelatedWork W2748952813 @default.
- W3159012904 hasRelatedWork W2778903907 @default.
- W3159012904 hasRelatedWork W2781364658 @default.
- W3159012904 hasRelatedWork W2809814494 @default.
- W3159012904 hasRelatedWork W2899084033 @default.
- W3159012904 hasRelatedWork W3041399715 @default.
- W3159012904 hasRelatedWork W4225326973 @default.
- W3159012904 hasRelatedWork W4247253261 @default.
- W3159012904 hasVolume "38" @default.
- W3159012904 isParatext "false" @default.
- W3159012904 isRetracted "false" @default.
- W3159012904 magId "3159012904" @default.
- W3159012904 workType "article" @default.